Matching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins

Apalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis

Early PSA Response as a Predictor and Mediator of Treatment Efficacy in Metastatic Hormone Sensitive Prostate Cancer